Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.
Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks. One patient had a partial response; four, stable disease; the remainder progressed. Mitoxantrone used in this dosage and schedule has minimal activity in patients with previously treated epithelial ovarian cancer.
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D008942:Mitoxantrone; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D000880:Anthraquinones; D008942:Mitoxantrone